AMG 581 + Placebo + Midazolam
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia or Schizoaffective Disorder
Conditions
Schizophrenia or Schizoaffective Disorder
Trial Timeline
Aug 1, 2015 → Feb 1, 2016
NCT ID
NCT02504476About AMG 581 + Placebo + Midazolam
AMG 581 + Placebo + Midazolam is a phase 1 stage product being developed by Amgen for Schizophrenia or Schizoaffective Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02504476. Target conditions include Schizophrenia or Schizoaffective Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia or Schizoaffective Disorder were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02504476 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia or Schizoaffective Disorder